Background: Ebola virus (EBOV) neutralizing antibody in plasma may reduce viral load following administration of plasma to patients with Ebola virus disease (EVD), but measurement of these antibodies is complex. Methods: Anti-EBOV antibody was measured by 2 neutralization and 2 enzyme-linked immunosorbent assays (ELISAs) in convalescent plasma (ECP) from 100 EVD survivor donors in Liberia. Viral load was assessed repetitively in patients with EVD participating in a clinical trial of enhanced standard of care plus ECP. Results: All 4 anti-EBOV assays were highly concordant for detection of EBOV antibody. Antibodies were not detected in plasma specimens obtained from 15 of 100 donors, including 7 with documented EBOV-positive reverse-transcription polymerase chain reaction during EVD. Viral load was reduced following each dose in the 2 clinical trial participants who received ECP with higher antibody levels but not in the 2 who received ECP with lower antibody levels. Conclusions: Recovery from EVD can occur with absence of detectable anti-EBOV antibody several months after disease onset. ELISAs may be useful to select ECP donors or identify ECP units that contain neutralizing antibody. ECP with higher anti-EBOV antibody levels may have greater effect on EBOV load-an observation that requires further investigation. Clinical Trials Registration: NCT02333578.
Background: Ebola virus (EBOV) neutralizing antibody in plasma may reduce viral load following administration of plasma to patients with Ebola virus disease (EVD), but measurement of these antibodies is complex. Methods: Anti-EBOV antibody was measured by 2 neutralization and 2 enzyme-linked immunosorbent assays (ELISAs) in convalescent plasma (ECP) from 100 EVD survivor donors in Liberia. Viral load was assessed repetitively in patients with EVD participating in a clinical trial of enhanced standard of care plus ECP. Results: All 4 anti-EBOV assays were highly concordant for detection of EBOV antibody. Antibodies were not detected in plasma specimens obtained from 15 of 100 donors, including 7 with documented EBOV-positive reverse-transcription polymerase chain reaction during EVD. Viral load was reduced following each dose in the 2 clinical trial participants who received ECP with higher antibody levels but not in the 2 who received ECP with lower antibody levels. Conclusions: Recovery from EVD can occur with absence of detectable anti-EBOV antibody several months after disease onset. ELISAs may be useful to select ECP donors or identify ECP units that contain neutralizing antibody. ECP with higher anti-EBOV antibody levels may have greater effect on EBOV load-an observation that requires further investigation. Clinical Trials Registration: NCT02333578.
Authors: Adrienne R Trombley; Leslie Wachter; Jeffrey Garrison; Valerie A Buckley-Beason; Jordan Jahrling; Lisa E Hensley; Randal J Schoepp; David A Norwood; Augustine Goba; Joseph N Fair; David A Kulesh Journal: Am J Trop Med Hyg Date: 2010-05 Impact factor: 2.345
Authors: John M Dye; Andrew S Herbert; Ana I Kuehne; James F Barth; Majidat A Muhammad; Samantha E Zak; Ramon A Ortiz; Laura I Prugar; William D Pratt Journal: Proc Natl Acad Sci U S A Date: 2012-03-12 Impact factor: 11.205
Authors: Marc-Antoine de La Vega; Grazia Caleo; Jonathan Audet; Xiangguo Qiu; Robert A Kozak; James I Brooks; Steven Kern; Anja Wolz; Armand Sprecher; Jane Greig; Kamalini Lokuge; David K Kargbo; Brima Kargbo; Antonino Di Caro; Allen Grolla; Darwyn Kobasa; James E Strong; Giuseppe Ippolito; Michel Van Herp; Gary P Kobinger Journal: J Clin Invest Date: 2015-11-09 Impact factor: 14.808
Authors: Katie A Howell; Xiangguo Qiu; Jennifer M Brannan; Christopher Bryan; Edgar Davidson; Frederick W Holtsberg; Anna Z Wec; Sergey Shulenin; Julia E Biggins; Robin Douglas; Sven G Enterlein; Hannah L Turner; Jesper Pallesen; Charles D Murin; Shihua He; Andrea Kroeker; Hong Vu; Andrew S Herbert; Marnie L Fusco; Elisabeth K Nyakatura; Jonathan R Lai; Zhen-Yong Keck; Steven K H Foung; Erica Ollmann Saphire; Larry Zeitlin; Andrew B Ward; Kartik Chandran; Benjamin J Doranz; Gary P Kobinger; John M Dye; M Javad Aman Journal: Cell Rep Date: 2016-05-05 Impact factor: 9.423
Authors: John Mair-Jenkins; Maria Saavedra-Campos; J Kenneth Baillie; Paul Cleary; Fu-Meng Khaw; Wei Shen Lim; Sophia Makki; Kevin D Rooney; Jonathan S Nguyen-Van-Tam; Charles R Beck Journal: J Infect Dis Date: 2014-07-16 Impact factor: 5.226
Authors: Jake Dunning; Foday Sahr; Amanda Rojek; Fiona Gannon; Gail Carson; Baimba Idriss; Thomas Massaquoi; Regina Gandi; Sebatu Joseph; Hassan K Osman; Timothy J G Brooks; Andrew J H Simpson; Ian Goodfellow; Lucy Thorne; Armando Arias; Laura Merson; Lyndsey Castle; Rebecca Howell-Jones; Raul Pardinaz-Solis; Benjamin Hope-Gill; Mauricio Ferri; Jennifer Grove; Mark Kowalski; Kasia Stepniewska; Trudie Lang; John Whitehead; Piero Olliaro; Mohammed Samai; Peter W Horby Journal: PLoS Med Date: 2016-04-19 Impact factor: 11.069
Authors: Pavlo Gilchuk; Charles D Murin; Robert W Cross; Philipp A Ilinykh; Kai Huang; Natalia Kuzmina; Viktoriya Borisevich; Krystle N Agans; Joan B Geisbert; Seth J Zost; Rachel S Nargi; Rachel E Sutton; Naveenchandra Suryadevara; Robin G Bombardi; Robert H Carnahan; Alexander Bukreyev; Thomas W Geisbert; Andrew B Ward; James E Crowe Journal: Cell Date: 2021-10-28 Impact factor: 41.582
Authors: Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio Journal: Biomedicines Date: 2022-08-22
Authors: Michael Ankcorn; Jennifer Gallacher; Samreen Ijaz; Yusri Taha; Heli Harvala; Sheila Maclennan; Emma C Thomson; Chris Davis; Joshua B Singer; Ana da Silva Filipe; Katherine Smollett; Marc Niebel; Malcolm G Semple; Richard S Tedder; Stuart McPherson Journal: J Hepatol Date: 2019-05-08 Impact factor: 25.083
Authors: Kamal Kant Sahu; Vishal Jindal; Ahmad Daniyal Siddiqui; Jan Cerny; Jonathan M Gerber Journal: J Med Virol Date: 2020-06-09 Impact factor: 20.693